Safety and Therapeutic Drug Monitoring of Cefazolin in Continuous Renal Replacement Therapy

Inclusion Criteria: Patients eligible to participate in the study must have a need for continuous renal replacement therapy (CRRT) of any modality: 1. CVVH-continuous veno-venous hemofiltration 2. CVVHD-continuous veno-venous hemodialysis 3. CVVHDF-continuous veno-venous hemodiafiltration Exclusion Criteria: Patients will be considered ineligible if they meet any of the following criteria: 1. History of any moderate or severe hypersensitivity or allergic reaction to cefazolin (a history of mild rash followed by uneventful re-exposure and/or red man syndrome is not a contraindication) 2. Any rapidly-progressing disease or immediately life-threatening illness (defined as imminent death within 48 hours in the opinion of the investigator) 3. Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the patient or the quality of study data 4. Females that are pregnant or breastfeeding